Clinical Trials Logo

Filter by:
NCT ID: NCT03782376 Completed - Crohn Disease Clinical Trials

A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

POWER
Start date: December 20, 2018
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the efficacy and safety of a single intravenous (IV) re-induction dose of approximately 6 milligram per kilogram (mg/kg) ustekinumab in participants with secondary loss of response (LoR) to subcutaneous (SC) every 8 Weeks (q8w) 90 mg ustekinumab maintenance therapy.

NCT ID: NCT03782181 Completed - Fibromyalgia Clinical Trials

Use of Whole Body Vibration in Patients With Fibromyalgia

Start date: January 7, 2019
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the efficacy of a 3-month program consisted of the use of whole body vibration (WBV) in patients with fibromyalgia in order to determine whether this intervention would be effective to short and medium-term improvement of symptoms in these patients.

NCT ID: NCT03781414 Completed - Clinical trials for Liver Transplant Rejection

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension

CONTRAIL I
Start date: October 7, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study was to investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 dose regimens in liver transplant recipients.

NCT ID: NCT03781167 Completed - Clinical trials for Parkinson's Disease (PD)

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Start date: April 29, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to assess the safety and tolerability of ABBV-951 (Foslevodopa/Foscarbidopa) in participants with Parkinson's disease (PD). This was a single-arm study with preplanned analyses conducted by dose subgroup (Low Dose or High Dose) based on the modal total daily dose (most frequent dose) over the treatment period.

NCT ID: NCT03780894 Completed - Polytrauma Clinical Trials

Transfusion of Red Blood Cells, Tranexamic Acid and Fibrinogen Concentrate for Severe Trauma Hemorrhage at Pre-hospital Phase of Care.

PRETIC
Start date: November 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-center, not-randomized, open-label, controlled pilot clinical trial. This study compares presence of Trauma Induced Coagulopathy (TIC) and acute traumatic hemorrhage treatment at pre-hospital phase of care with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC) with the current treatment based on the administration of Crystalloids and TXA.

NCT ID: NCT03780673 Completed - Liver Cirrhoses Clinical Trials

Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development

2018-001698-25
Start date: January 3, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF

NCT ID: NCT03780517 Completed - Clinical trials for Advanced Nonhaematologic Malignancies

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Start date: December 12, 2018
Phase: Phase 1
Study type: Interventional

This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738.

NCT ID: NCT03780426 Completed - Essential Tremor Clinical Trials

tSMS in Essential Tremor

Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

This is randomized double-blind study to study the hypothesis that transcranial static magnetic field stimulation of the primary motor cortex improves tremor in patients with essential tremor. Half of the patients will receive tSMS of the left hemisphere and the other half of the right hemisphere.

NCT ID: NCT03779841 Completed - Clinical trials for Post-Operative Atrial Fibrillation

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

This was a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of ganglionic plexi, to prevent Post-Operative Atrial Fibrillation (POAF) in patients undergoing open-chest cardiac surgery.

NCT ID: NCT03777449 Completed - Peri-Implantitis Clinical Trials

The Morphology of the Peri-Implantitis Defects: A Cone-Beam Computed Analysis

Start date: August 10, 2018
Phase:
Study type: Observational [Patient Registry]

To study the morphology of the peri-implant defects using cone-beam computed tomography based on a priori case definition of peri-implantitis (≥3mm of radiographic bone loss + inflammatory clinical parameters) Diagnosis of peri‐implantitis requires: - Presence of bleeding and/or suppuration on gentle probing. - Increased probing depth compared to previous examinations. - Presence of bone loss beyond crestal bone level changes resulting from initial bone remodeling. In the absence of previous examination data diagnosis of peri‐implantitis can be based on the combination of: - Presence of bleeding and/or suppuration on gentle probing. - Probing depths of ≥6 mm. - Bone levels ≥3 mm apical of the most coronal portion of the intraosseous part of the implant.